Phesi’s report of the world’s most-studied diseases has become a holiday tradition, and this year’s list features few surprises. | Phesi’s report of the world’s most-studied diseases has become a ...

For the third year in a row, Fierce Biotech’s Layoff Tracker is topping the tree as the story with the highest number of ...

Adding another potential wrinkle to the industry’s work with China is the Biosecure Act, a piece of China-targeting national ...

“Following the initial pause, the FDA has placed the trial on a partial clinical hold,” the spokesperson explained.

One of the main threads running through our most-read stories of 2025—as much as ever in the medtech industry writ large—is ...

Amid news of the splashy $4.8 billion Amicus buy, BioMarin has slipped in the discontinuation of a genetic liver disease ...

Windtree Therapeutics has not been shy about its desire to become a revenue-generating company, even when achieving that goal ...

Edwards Lifesciences has claimed an FDA approval for its Sapien M3 transcatheter mitral valve replacement system—marking the ...

William Blair has hand-picked its top five stock recommendations for 2026, selections that include three clinical-stage ...

Eli Lilly has shown patients maintained most of their weight loss after switching from injectable GLP-1s to its oral drug ...

A flurry of deal-making hasn’t let up as 2025 comes to a close, with Roche subsidiary Genentech getting in on the action and ...

After taking a shot at becoming a neuroscience biotech, buzzy Bay Area AI outfit Verge Genomics is dropping its only clinical ...